glp 1 side effects cancer GLP-1 receptor agonists—the class of drugs behind Ozempic, Wegovy, and Mounjaro—may do more than regulate blood sugar and weight. In an analysis of more than 6,800 colon patients across Glucagon-like peptide 1 receptor agonists
Description
PubMed, 2024 Glucagon-like peptide-1 receptor agonists and muscle strength changes in older adults British Journal of Pharmacology, 2025 Consuming more protein may protect patients taking an anti-obesity drug from muscle loss Endocrine Society, ENDO 2025 Preserving Lean Body Mass in Patients Taking GLP-1 for Weight Loss Mass General Advances in Motion GLP-1s and Lean Mass: What the Research Shows ACE Certified, June 2025 New GLP-1 Therapies Enhance Quality of Weight Loss by Improving Muscle Preservation American Diabetes Association, 2025 Impact of GLP-1 Receptor Agonist Therapy in Patients at High Risk for Sarcopenia Current Nutrition Reports, Springer, 2025
This article examines the emerging evidence, proposed mechanisms involving brain reward pathways, and important safety considerations for clinicians and patients navigating this investigational area
De Waele K, Ishkanian SL, Bogarin R, Miranda CA, Ghatei MA, Bloom SR, et al
It is either marketed as a research chemical, labeled "not for human consumption," or it is being sold in violation of federal law
Hunger increases, fullness becomes less reliable, and metabolic adaptation makes maintenance difficult
PlexusDx recommends TSH testing before starting GLP-1 therapy, then every 612 weeks during your first year
